Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- PMID: 19887545
- DOI: 10.1158/1535-7163.MCT-09-0463
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Abstract
Wee1 is a tyrosine kinase that phosphorylates and inactivates CDC2 and is involved in G(2) checkpoint signaling. Because p53 is a key regulator in the G(1) checkpoint, p53-deficient tumors rely only on the G(2) checkpoint after DNA damage. Hence, such tumors are selectively sensitized to DNA-damaging agents by Wee1 inhibition. Here, we report the discovery of a potent and selective small-molecule inhibitor of Wee1 kinase, MK-1775. This compound inhibits phosphorylation of CDC2 at Tyr15 (CDC2Y15), a direct substrate of Wee1 kinase in cells. MK-1775 abrogates G(2) DNA damage checkpoint, leading to apoptosis in combination with DNA-damaging chemotherapeutic agents such as gemcitabine, carboplatin, and cisplatin selectively in p53-deficient cells. In vivo, MK-1775 potentiates tumor growth inhibition by these agents, and cotreatment does not significantly increase toxicity. The enhancement of antitumor effect by MK-1775 was well correlated with inhibition of CDC2Y15 phosphorylation in tumor tissue and skin hair follicles. Our data indicate that Wee1 inhibition provides a new approach for treatment of multiple human malignancies.
Similar articles
-
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.Cancer Biol Ther. 2010 Apr 1;9(7):514-22. doi: 10.4161/cbt.9.7.11115. Epub 2010 Apr 1. Cancer Biol Ther. 2010. PMID: 20107315
-
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.Clin Cancer Res. 2011 May 1;17(9):2799-806. doi: 10.1158/1078-0432.CCR-10-2580. Epub 2011 Mar 9. Clin Cancer Res. 2011. PMID: 21389100 Free PMC article.
-
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.Curr Clin Pharmacol. 2010 Aug;5(3):186-91. doi: 10.2174/157488410791498824. Curr Clin Pharmacol. 2010. PMID: 20406171 Review.
-
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.Mol Cancer Ther. 2013 Aug;12(8):1442-52. doi: 10.1158/1535-7163.MCT-13-0025. Epub 2013 May 22. Mol Cancer Ther. 2013. PMID: 23699655
-
Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.Expert Opin Investig Drugs. 2018 Sep;27(9):741-751. doi: 10.1080/13543784.2018.1511700. Epub 2018 Aug 21. Expert Opin Investig Drugs. 2018. PMID: 30102076 Review.
Cited by
-
Drug development and clinical trials--the path to an approved cancer drug.Nat Rev Clin Oncol. 2012 Feb 28;9(4):215-22. doi: 10.1038/nrclinonc.2012.22. Nat Rev Clin Oncol. 2012. PMID: 22371130 Review.
-
Exploiting replicative stress to treat cancer.Nat Rev Drug Discov. 2015 Jun;14(6):405-23. doi: 10.1038/nrd4553. Epub 2015 May 8. Nat Rev Drug Discov. 2015. PMID: 25953507 Review.
-
Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling.Cancers (Basel). 2021 Feb 20;13(4):885. doi: 10.3390/cancers13040885. Cancers (Basel). 2021. PMID: 33672646 Free PMC article.
-
Targeting lung cancer through inhibition of checkpoint kinases.Front Genet. 2015 Feb 27;6:70. doi: 10.3389/fgene.2015.00070. eCollection 2015. Front Genet. 2015. PMID: 25774168 Free PMC article.
-
Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption.Mol Cell Biol. 2012 Oct;32(20):4226-36. doi: 10.1128/MCB.00412-12. Epub 2012 Aug 20. Mol Cell Biol. 2012. PMID: 22907750 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous